Back to Search Start Over

Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study

Authors :
Philippe Guerci
Hugo Bellut
Mokhtar Mokhtari
Julie Gaudefroy
Nicolas Mongardon
Claire Charpentier
Guillaume Louis
Parvine Tashk
Clément Dubost
Stanislas Ledochowski
Antoine Kimmoun
Thomas Godet
Julien Pottecher
Jean-Marc Lalot
Emmanuel Novy
David Hajage
Adrien Bouglé
AZUREA research network
Université de Lorraine (UL)
Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Défaillance Cardiovasculaire Aiguë et Chronique (DCAC)
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
Sorbonne Université (SU)
Institut de cardiologie [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP]
Service d'anesthésiologie et soins intensifs [CHU Pitié-Salpêtrière]
Hôpital de Hautepierre [Strasbourg]
Les Hôpitaux Universitaires de Strasbourg (HUS)
Institut Mondor de Recherche Biomédicale (IMRB)
Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Hôpital Henri Mondor
Centre hospitalier universitaire de Nantes (CHU Nantes)
Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville)
CIC - CHU Bichat
Institut National de la Santé et de la Recherche Médicale (INSERM)
Hôpital d'Instruction des Armées Begin
Service de Santé des Armées
CHU Estaing [Clermont-Ferrand]
Mitochondrie, stress oxydant et protection musculaire (MSP)
Université de Strasbourg (UNISTRA)
Fédération de Médecine Translationnelle de Strasbourg (FMTS)
Centre Hospitalier Emile Durkheim [Epinal] (CH Epinal / CHED)
Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Service de Biostatistique Santé Publique et Information Médicale [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
Service d'Anesthésie réanimation [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
CH Pierre Oudot Bourgoin-Jallieu
CHU Clermont-Ferrand
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM )
Source :
Critical Care, Vol 23, Iss 1, Pp 1-13 (2019), Critical Care, Critical Care, BioMed Central, 2019, 23 (1), pp.371. ⟨10.1186/s13054-019-2649-5⟩
Publication Year :
2019
Publisher :
BMC, 2019.

Abstract

Background There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy. Methods This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy. Results Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5–18] days. The Simplified Acute Physiology Score II was 47 [36–63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively). Conclusions S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival. Trial registration clinicaltrials.gov, NCT03506191

Details

Language :
English
ISSN :
13648535 and 1466609X
Volume :
23
Issue :
1
Database :
OpenAIRE
Journal :
Critical Care
Accession number :
edsair.doi.dedup.....038150a304b15ebfb36529d05f8185ce